Interaction of 5-HT2Aand 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 728-734

  Fantegrossi, William E ^a,b   Simoneau, J ^b   Cohen, M S ^b   Zimmerman, S M ^a   Henson, C M ^a   Rice, K C ^c   Woods, J H ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b EMORY UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; KETANSERIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; VOLINANSERIN; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; 6 CHLORO 5 METHYL 1 ((2 (2 METHYLPYRID 3 YLOXY)PYRID 5 YL)CARBAMOYL)INDOLINE; 6-CHLORO-5-METHYL-1-((2-(2-METHYLPYRID-3-YLOXY)PYRID-5-YL)CARBAMOYL)INDOLINE; AMINOPYRIDINE DERIVATIVE; AMPHETAMINE DERIVATIVE; ETHYLAMINE; FLUOROBENZENE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; SPIRO COMPOUND; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SELECTIVITY; HEAD TWITCH; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; ANIMAL; ANIMAL BEHAVIOR; HEAD; METABOLISM; MOUSE STRAIN; MOVEMENT (PHYSIOLOGY);

AMINOPYRIDINES; AMPHETAMINES; ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLAMINES; FLUOROBENZENES; HALLUCINOGENS; HEAD; INDOLES; KETANSERIN; MALE; MICE; MICE, INBRED STRAINS; MOVEMENT; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SPIRO COMPOUNDS; SULFONAMIDES;

EID: 78649549071     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.172247     Document Type: Article

References (35)

1. 125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther 255:843-857.
2. Berendsen HH and Broekkamp CL (1990) Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 101:667-673.
3. Braden MR, Parrish JC, Naylor JC, and Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956-1964.
4. Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, and Airey DC (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology 209:163-174.
5. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, and Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314:310-319.
6. Colpaert FC and Janssen PA (1983) The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22:993-1000.
7. Corne SJ, Pickering RW, and Warner BT (1963) A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol Chemother 20:106-120.
8. Corne SJ and Pickering RW (1967) A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia 11:65-78.
9. Darmani NA, Martin BR, and Glennon RA (1990a) Withdrawal from chronic treatment with (±)-DOI causes super-sensitivity to 5-HT2 receptor-induced head-twitch behaviour in mice. Eur J Pharmacol 186:115-118.
10. Darmani NA, Martin BR, and Glennon RA (1992) Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J Pharmacol Exp Ther 262:692-698.
11. Darmani NA, Martin BR, Pandey U, and Glennon RA (1990b) Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36:901-906.
12. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, and Woods JH (2005) Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology 181:496-503.
13. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, and Woods JH (2006) Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83:122-129.
14. Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, and Woods JH (2004) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology 173:270-277.
15. Fantegrossi WE, Murnane KS, and Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17-33.
16. Fiorella D, Helsley S, Lorrain DS, Rabin RA, and Winter JC (1995b) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: The mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology 121:364-372.
17. Fiorella D, Rabin RA, and Winter JC (1995a) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology 121:347-356.
18. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439-452.
19. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, and Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836-8843.
20. Goodwin GM and Green AR (1985) A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84:743-753.
21. Green AR, O'Shaughnessy K, Hammond M, Schächter M, and Grahame-Smith DG (1983) Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology 22:573-578.
22. Handley SL and Singh L (1986) Neurotransmitters and shaking behaviour - more than a "gut-bath" for the brain? Trends Pharmacol Sci 7:324-328.
23. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, and Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370:114-123.
24. Lucki I, Nobler MS, and Frazer A (1984) Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 228:133-139.
25. 3H-ketanserin. J Neurosci 9:3482-3490.
26. Ortmann R, Bischoff S, Radeke E, Buech O, and Delini-Stula A (1982) Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers. Naunyn Schmiedebergs Arch Pharmacol 321:265-270.
27. Peroutka SJ, Lebovitz RM, and Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science 212:827-829.
28. Schmid CL, Raehal KM, and Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079-1084.
29. Schreiber R, Brocco M, and Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99-102.
30. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, and Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101-112.
31. Smith RL, Barrett RJ, and Sanders-Bush E (1999) Mechanism of tolerance development to 2,5-dimethoxy-4-iodoamphetamine in rats: down-regulation of the 5-HT2A, but not 5-HT2C, receptor. Psychopharmacology 144:248-254.
32. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, and Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med 363:245-256.
33. Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, and Kennett GA (2001) Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav 69:643-652.
34. Willins DL and Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706.
35. Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, and Rabin RA (1999) Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64:283-293.